A BILL 
To amend titles XVIII and XIX of the Social Security Act 
and title XXVII of the Public Health Service Act to 
provide for coverage of certain drugs used in the treat-
ment or management of a rare disease or condition, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Access to Rare Indica-
4
tions Act of 2020’’. 
5
04:54 Oct 27, 2020
H8467
2 
•HR 8467 IH
SEC. 2. COVERAGE OF CERTAIN DRUGS USED IN TREAT-
1
MENT OR MANAGEMENT OF RARE DISEASE 
2
OR CONDITION. 
3
(a) MEDICARE.— 
4
(1) IN
GENERAL.—Section 1861(t)(2) of the 
5
Social Security Act (42 U.S.C. 1395x(t)(2)) is 
6
amended— 
7
(A) in subparagraph (A), by inserting after 
8
‘‘regimen’’ the following: ‘‘, or in the treatment 
9
or management of a disease or condition affect-
10
ing 200,000 or fewer individuals in the United 
11
States,’’; and 
12
(B) in subparagraph (B)(ii)— 
13
(i) in subclause (I), by striking ‘‘, or’’ 
14
at the end and inserting a semicolon; 
15
(ii) in subclause (II), by striking the 
16
period at the end and inserting ‘‘; or’’; and 
17
(iii) by adding at the end the fol-
18
lowing new subclause: 
19
‘‘(III) in the case that the drug is used in the 
20
treatment or management of a disease or condition 
21
affecting 200,000 or fewer individuals in the United 
22
States, such use is supported by peer-reviewed lit-
23
erature, clinical guidelines, or expert opinion within 
24
the National Institutes of Health Rare Diseases 
25
04:54 Oct 27, 2020
H8467
3 
•HR 8467 IH
Clinical Research Network consortia or its partici-
1
pating clinical centers.’’. 
2
(2) PROHIBITION
OF
COVERAGE
EXCLUSIONS 
3
FOR FORMULARIES UNDER MEDICARE PART D.—Sec-
4
tion 1860D–4(b)(3) of the Social Security Act (42 
5
U.S.C. 1395w–104(b)(3)) is amended by adding at 
6
the end the following new subparagraph: 
7
‘‘(I) PROHIBITION OF CERTAIN COVERAGE 
8
EXCLUSIONS.— 
9
‘‘(i) IN GENERAL.—If the PDP spon-
10
sor of a prescription drug plan uses a for-
11
mulary, such sponsor may not impose a 
12
limitation or exclusion of benefits with re-
13
spect to coverage of a rare disease covered 
14
part D drug (as defined in clause (ii)) in-
15
cluded in such formulary. 
16
‘‘(ii) RARE DISEASE COVERED PART D 
17
DRUG.—For purposes of this subpara-
18
graph, the term ‘rare disease covered part 
19
D drug’ means a covered part D drug— 
20
‘‘(I) used in the treatment or 
21
management of a disease or condition 
22
affecting 200,000 or fewer individuals 
23
in the United States; and 
24
04:54 Oct 27, 2020
H8467
4 
•HR 8467 IH
‘‘(II) the use of which is sup-
1
ported by peer-reviewed literature, 
2
clinical guidelines, or expert opinion 
3
within the National Institutes of 
4
Health Rare Diseases Clinical Re-
5
search Network consortia or its par-
6
ticipating clinical centers.’’. 
7
(3) EFFECTIVE DATE.—The amendments made 
8
by this subsection apply with respect to items and 
9
services furnished on or after the date that is 30 
10
days after the date of the enactment of this Act. 
11
(b) MEDICAID.— 
12
(1) IN GENERAL.—Section 1927(k)(6) of the 
13
Social Security Act (42 U.S.C. 1396r–8(k)(6)) is 
14
amended— 
15
(A) by striking ‘‘, or’’ and inserting a 
16
comma; and 
17
(B) by inserting before the period the fol-
18
lowing: ‘‘, or the use of which is related to the 
19
treatment or management of a disease or condi-
20
tion affecting 200,000 or fewer individuals in 
21
the United States and is supported by peer-re-
22
viewed literature, clinical guidelines, or expert 
23
opinion within the National Institutes of Health 
24
04:54 Oct 27, 2020
H8467
5 
•HR 8467 IH
Rare Diseases Clinical Research Network con-
1
sortia or its participating clinical centers’’. 
2
(2) PROHIBITION
OF
COVERAGE
EXCLUSIONS 
3
FOR FORMULARIES.—Section 1927(d)(4) of the So-
4
cial Security Act (42 U.S.C. 1396r–8(d)(4)) is 
5
amended— 
6
(A) in subparagraph (C), by striking ‘‘A 
7
covered outpatient drug’’ and inserting ‘‘Sub-
8
ject to subparagraph (E), a covered outpatient 
9
drug’’; 
10
(B) by redesignating subparagraph (E) as 
11
subparagraph (F); and 
12
(C) by inserting after subparagraph (D) 
13
the following new subparagraph: 
14
‘‘(E) Notwithstanding subparagraph (C), 
15
the State may not impose a limitation or exclu-
16
sion of benefits with respect to coverage of a 
17
covered outpatient drug that is— 
18
‘‘(i) used in the treatment or manage-
19
ment of a disease or condition affecting 
20
200,000 or fewer individuals in the United 
21
States; and 
22
‘‘(ii) the use of which is supported by 
23
peer-reviewed literature, clinical guidelines, 
24
or expert opinion within the National Insti-
25
04:54 Oct 27, 2020
H8467
6 
•HR 8467 IH
tutes of Health Rare Diseases Clinical Re-
1
search Network consortia or its partici-
2
pating clinical centers.’’. 
3
(3) EFFECTIVE DATE.—The amendments made 
4
by this subsection apply with respect to covered out-
5
patient drugs furnished on or after the date that is 
6
30 days after the date of the enactment of this Act. 
7
(c) PRIVATE HEALTH INSURANCE.— 
8
(1) IN GENERAL.—Subpart II of part A of title 
9
XXVII of the Public Health Service Act (42 U.S.C. 
10
300gg–11 et seq.) is amended by adding at the end 
11
the following new section: 
12
‘‘SEC. 2730. COVERAGE OF CERTAIN DRUGS USED IN TREAT-
13
MENT OR MANAGEMENT OF RARE DISEASE 
14
OR CONDITION. 
15
‘‘(a) IN GENERAL.—A group health plan or a health 
16
insurance issuer offering group or individual health insur-
17
ance coverage shall provide coverage for a drug— 
18
‘‘(1) approved by the Food and Drug Adminis-
19
tration; 
20
‘‘(2) used in the treatment or management of 
21
a disease or condition affecting 200,000 or fewer in-
22
dividuals in the United States; and 
23
‘‘(3) the use of which is supported by peer-re-
24
viewed literature, clinical guidelines, or expert opin-
25
04:54 Oct 27, 2020
H8467
7 
•HR 8467 IH
ion within the National Institutes of Health Rare 
1
Diseases Clinical Research Network consortia or its 
2
participating clinical centers. 
3
‘‘(b) PROHIBITION OF CERTAIN COVERAGE EXCLU-
4
SIONS.—A group health plan or a health insurance issuer 
5
offering group or individual health insurance coverage 
6
may not impose a limitation or exclusion of benefits with 
7
respect to coverage of a drug described in subsection (a) 
8
other than a limitation or exclusion of benefits with re-
9
spect to a use of such drug identified as contraindicated 
10
by the Food and Drug Administration.’’. 
11
(2) EFFECTIVE DATE.—The amendment made 
12
by this subsection applies with respect to plan years 
13
beginning on or after the date that is 30 days after 
14
the date of the enactment of this Act. 
15
Æ 
04:54 Oct 27, 2020
H8467
